We demonstrated the generality of this notion using human Hep3B liver cancer cells with focal amplification of the growth factor gene FGF19, which represent liver cancers being targeted in clinical trials using fisogatinib to inhibit FGFR4, the receptor for FGF19 (ref. 25). The gene discussed is FGF19; the disease is liver cancer.